The small molecule CMO/CDMO market size has grown strongly in recent years. It will grow from $46.83 billion in 2023 to $50.58 billion in 2024 at a compound annual growth rate (CAGR) of 8%. The growth observed in the historic period can be attributed to several factors, including favorable government support, the adoption of cost-effective solutions, the increasing complexity in drug development processes, industry consolidation, and a strategic focus on core competencies. These elements collectively contributed to the positive trajectory and expansion of small-molecule Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) during the historic period.
The small molecule CMO/CDMO market size is expected to see strong growth in the next few years. It will grow to $68.04 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The anticipated growth in the forecast period can be attributed to factors such as the rise in drug pipelines, globalization of pharmaceutical operations, increasing demand for flexible manufacturing solutions, expertise in regulatory compliance, and the convergence of biopharmaceuticals. Key trends expected in the forecast period include the adoption of sustainable and green manufacturing practices, increased collaboration and partnerships within the industry, a focus on personalized medicine and niche therapies, the emergence of virtual and virtual-to-reality companies, integration of digital technologies, and the implementation of rapid response manufacturing strategies.
The small-molecule CMO/CDMO market is expected to experience growth due to the rising demand for pharmaceuticals. The pharmaceutical industry involves the discovery, development, and production of drugs and medicines by various entities, both governmental and private. Small-molecule CMO/CDMO services in the pharmaceutical industry are utilized to outsource tasks such as the development, manufacturing, and packaging of small-molecule drugs. This outsourcing allows pharmaceutical companies to reduce costs, save time, and streamline their processes. According to reports from IQVIA Inc. in May 2021, the projected total expenditure on pharmaceuticals in the US is anticipated to range between $380 to $400 billion by 2025, reflecting a compound annual growth rate of 3% from $359 billion in 2020. This projection indicates a growing demand for pharmaceuticals and, consequently, drives the growth of the small-molecule CMO/CDMO market.
Major companies in the small-molecule CMO/CDMO market are focusing on innovative technologies to enhance CDMO services, such as the state-of-the-art small-molecule platform in Shanghai. This platform represents cutting-edge technological innovations aimed at developing and producing small-molecule drugs more efficiently. In June 2023, Porton Pharma Solutions Ltd., a China-based pharmaceutical company, launched a state-of-the-art small-molecule platform in Shanghai. This platform adopts a holistic approach by combining advanced technologies and methodologies to advance the entire lifecycle of small-molecule pharmaceuticals. It offers one-stop-shop solutions, flexibility, availability, and digital transformation.
In March 2023, Catalent Inc., a US-based pharmaceutical company, entered into a partnership with Grünentha GmbH, a Germany-based pharmaceutical company. This partnership is focused on expediting clinical development timelines for an orally dosed small molecule in Grünenthal's pipeline. The collaboration aims to improve the bioavailability of the small molecule and reduce the Phase 1 development timeline. Grünenthal GmbH is actively engaged in partnerships and agreements with contract development and manufacturing organizations (CDMOs).
Major companies operating in the small molecule CMO/CDMO market report are Patheon NV (Thermo Fisher Scientific), GlaxoSmithKline, Johnson Matthey plc, Lonza Group Ltd., WuXi AppTec, Catalent Inc., Aurobindo Pharma, Fareva, Aesica Pharmaceuticals Limited, Siegfried holdings AG, Recipharm AB, Jubilant Life Sciences Limited, Almac Group, Piramal Pharma Solutions, Oxford Chemicals Inc., Syngene International Limited, Novasep, Pfizer CentreOne, GVK Biosciences, ChemPartner, Avid Bioservices Inc., Dishman Carbogen Amcis Ltd, ProChem Inc., Metrics Contract Services.
North America was the largest region in the Small Molecule CMO/CDMO market in 2023. The regions covered in the Small Molecule CMO/CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the Small Molecule CMO/CDMO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The small-molecule contract manufacturing organization (CMO) or contract development and manufacturing organization (CDMO) market consists of revenues earned by entities by providing services such as drug development services, process scale-up, quality control and testing, technology transfer, and clinical trial support. The market value includes the value of related goods sold by the service provider or included within the service offering. The small-molecule contract manufacturing organization (CMO) or contract development and manufacturing organization (CDMO) market also includes sales of active pharmaceutical ingredients, drug intermediates, and drug formulation. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
A small-molecule Contract Manufacturing Organization (CMO) or Contract Development and Manufacturing Organization (CDMO) is a business entity that offers services to pharmaceutical companies on a contractual basis. These services encompass various aspects of the pharmaceutical development lifecycle, including contract development, manufacturing, and packaging of small-molecule drugs. Small-molecule CMOs/CDMOs play a crucial role in assisting other companies in the pharmaceutical industry to complete projects and navigate through the regulatory submission process.
Small-molecule Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) are primarily classified into two categories, small-molecule drug products and small-molecule Active Pharmaceutical Ingredient (API). The term "small-molecule drug product" denotes the final form of a medicinal product that incorporates an active pharmaceutical ingredient composed of small molecules. This involves comprehensive stages, including clinical, commercial, and preclinical development. These drug products find applications in therapeutic areas such as oncology, neurology, infectious diseases, cardiovascular diseases, respiratory disorders, metabolic disorders, among others. The end-users of these services are entities specializing in cardiovascular, oncology, diabetes, and immunological disorders.
The small-molecule CMO/CDMO market research report is one of a series of new reports that provides small-molecule CMO/CDMO market statistics, including small-molecule CMO/CDMO industry global market size, regional shares, competitors with a small-molecule CMO/CDMO market share, detailed small-molecule CMO/CDMO market segments, market trends and opportunities, and any further data you may need to thrive in the small-molecule CMO/CDMO industry. This small-molecule CMO/CDMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The small molecule CMO/CDMO market size is expected to see strong growth in the next few years. It will grow to $68.04 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The anticipated growth in the forecast period can be attributed to factors such as the rise in drug pipelines, globalization of pharmaceutical operations, increasing demand for flexible manufacturing solutions, expertise in regulatory compliance, and the convergence of biopharmaceuticals. Key trends expected in the forecast period include the adoption of sustainable and green manufacturing practices, increased collaboration and partnerships within the industry, a focus on personalized medicine and niche therapies, the emergence of virtual and virtual-to-reality companies, integration of digital technologies, and the implementation of rapid response manufacturing strategies.
The small-molecule CMO/CDMO market is expected to experience growth due to the rising demand for pharmaceuticals. The pharmaceutical industry involves the discovery, development, and production of drugs and medicines by various entities, both governmental and private. Small-molecule CMO/CDMO services in the pharmaceutical industry are utilized to outsource tasks such as the development, manufacturing, and packaging of small-molecule drugs. This outsourcing allows pharmaceutical companies to reduce costs, save time, and streamline their processes. According to reports from IQVIA Inc. in May 2021, the projected total expenditure on pharmaceuticals in the US is anticipated to range between $380 to $400 billion by 2025, reflecting a compound annual growth rate of 3% from $359 billion in 2020. This projection indicates a growing demand for pharmaceuticals and, consequently, drives the growth of the small-molecule CMO/CDMO market.
Major companies in the small-molecule CMO/CDMO market are focusing on innovative technologies to enhance CDMO services, such as the state-of-the-art small-molecule platform in Shanghai. This platform represents cutting-edge technological innovations aimed at developing and producing small-molecule drugs more efficiently. In June 2023, Porton Pharma Solutions Ltd., a China-based pharmaceutical company, launched a state-of-the-art small-molecule platform in Shanghai. This platform adopts a holistic approach by combining advanced technologies and methodologies to advance the entire lifecycle of small-molecule pharmaceuticals. It offers one-stop-shop solutions, flexibility, availability, and digital transformation.
In March 2023, Catalent Inc., a US-based pharmaceutical company, entered into a partnership with Grünentha GmbH, a Germany-based pharmaceutical company. This partnership is focused on expediting clinical development timelines for an orally dosed small molecule in Grünenthal's pipeline. The collaboration aims to improve the bioavailability of the small molecule and reduce the Phase 1 development timeline. Grünenthal GmbH is actively engaged in partnerships and agreements with contract development and manufacturing organizations (CDMOs).
Major companies operating in the small molecule CMO/CDMO market report are Patheon NV (Thermo Fisher Scientific), GlaxoSmithKline, Johnson Matthey plc, Lonza Group Ltd., WuXi AppTec, Catalent Inc., Aurobindo Pharma, Fareva, Aesica Pharmaceuticals Limited, Siegfried holdings AG, Recipharm AB, Jubilant Life Sciences Limited, Almac Group, Piramal Pharma Solutions, Oxford Chemicals Inc., Syngene International Limited, Novasep, Pfizer CentreOne, GVK Biosciences, ChemPartner, Avid Bioservices Inc., Dishman Carbogen Amcis Ltd, ProChem Inc., Metrics Contract Services.
North America was the largest region in the Small Molecule CMO/CDMO market in 2023. The regions covered in the Small Molecule CMO/CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the Small Molecule CMO/CDMO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The small-molecule contract manufacturing organization (CMO) or contract development and manufacturing organization (CDMO) market consists of revenues earned by entities by providing services such as drug development services, process scale-up, quality control and testing, technology transfer, and clinical trial support. The market value includes the value of related goods sold by the service provider or included within the service offering. The small-molecule contract manufacturing organization (CMO) or contract development and manufacturing organization (CDMO) market also includes sales of active pharmaceutical ingredients, drug intermediates, and drug formulation. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
A small-molecule Contract Manufacturing Organization (CMO) or Contract Development and Manufacturing Organization (CDMO) is a business entity that offers services to pharmaceutical companies on a contractual basis. These services encompass various aspects of the pharmaceutical development lifecycle, including contract development, manufacturing, and packaging of small-molecule drugs. Small-molecule CMOs/CDMOs play a crucial role in assisting other companies in the pharmaceutical industry to complete projects and navigate through the regulatory submission process.
Small-molecule Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) are primarily classified into two categories, small-molecule drug products and small-molecule Active Pharmaceutical Ingredient (API). The term "small-molecule drug product" denotes the final form of a medicinal product that incorporates an active pharmaceutical ingredient composed of small molecules. This involves comprehensive stages, including clinical, commercial, and preclinical development. These drug products find applications in therapeutic areas such as oncology, neurology, infectious diseases, cardiovascular diseases, respiratory disorders, metabolic disorders, among others. The end-users of these services are entities specializing in cardiovascular, oncology, diabetes, and immunological disorders.
The small-molecule CMO/CDMO market research report is one of a series of new reports that provides small-molecule CMO/CDMO market statistics, including small-molecule CMO/CDMO industry global market size, regional shares, competitors with a small-molecule CMO/CDMO market share, detailed small-molecule CMO/CDMO market segments, market trends and opportunities, and any further data you may need to thrive in the small-molecule CMO/CDMO industry. This small-molecule CMO/CDMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Small Molecule CMO/CDMO Market Characteristics3. Small Molecule CMO/CDMO Market Trends and Strategies32. Global Small Molecule CMO/CDMO Market Competitive Benchmarking33. Global Small Molecule CMO/CDMO Market Competitive Dashboard34. Key Mergers and Acquisitions in the Small Molecule CMO/CDMO Market
4. Small Molecule CMO/CDMO Market - Macro Economic Scenario
5. Global Small Molecule CMO/CDMO Market Size and Growth
6. Small Molecule CMO/CDMO Market Segmentation
7. Small Molecule CMO/CDMO Market Regional and Country Analysis
8. Asia-Pacific Small Molecule CMO/CDMO Market
9. China Small Molecule CMO/CDMO Market
10. India Small Molecule CMO/CDMO Market
11. Japan Small Molecule CMO/CDMO Market
12. Australia Small Molecule CMO/CDMO Market
13. Indonesia Small Molecule CMO/CDMO Market
14. South Korea Small Molecule CMO/CDMO Market
15. Western Europe Small Molecule CMO/CDMO Market
16. UK Small Molecule CMO/CDMO Market
17. Germany Small Molecule CMO/CDMO Market
18. France Small Molecule CMO/CDMO Market
19. Italy Small Molecule CMO/CDMO Market
20. Spain Small Molecule CMO/CDMO Market
21. Eastern Europe Small Molecule CMO/CDMO Market
22. Russia Small Molecule CMO/CDMO Market
23. North America Small Molecule CMO/CDMO Market
24. USA Small Molecule CMO/CDMO Market
25. Canada Small Molecule CMO/CDMO Market
26. South America Small Molecule CMO/CDMO Market
27. Brazil Small Molecule CMO/CDMO Market
28. Middle East Small Molecule CMO/CDMO Market
29. Africa Small Molecule CMO/CDMO Market
30. Small Molecule CMO/CDMO Market Competitive Landscape and Company Profiles
31. Small Molecule CMO/CDMO Market Other Major and Innovative Companies
35. Small Molecule CMO/CDMO Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Small Molecule CMO/CDMO Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on small molecule cmo/cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description:
Where is the largest and fastest growing market for small molecule cmo/cdmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The small molecule cmo/cdmo market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Small Molecule Drug Product; Small Molecule API2) By Stage Type: Clinical; Commercial; Preclinical
3) By Therapeutic Area: Oncology; Neurology; Infectious Disease; Cardiovascular Disease; Respiratory Disorders; Metabolic Disorders; Other Therapeutics.
4) By Application: Cardiovascular; Oncology; Diabetes; Immunological Disorders
Key Companies Mentioned: Patheon NV (Thermo Fisher Scientific); GlaxoSmithKline; Johnson Matthey plc; Lonza Group Ltd.; WuXi AppTec
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Patheon NV (Thermo Fisher Scientific)
- GlaxoSmithKline
- Johnson Matthey plc
- Lonza Group Ltd.
- WuXi AppTec
- Catalent Inc.
- Aurobindo Pharma
- Fareva
- Aesica Pharmaceuticals Limited
- Siegfried holdings AG
- Recipharm AB
- Jubilant Life Sciences Limited
- Almac Group
- Piramal Pharma Solutions
- Oxford Chemicals Inc.
- Syngene International Limited
- Novasep
- Pfizer CentreOne
- GVK Biosciences
- ChemPartner
- Avid Bioservices Inc.
- Dishman Carbogen Amcis Ltd
- ProChem Inc.
- Metrics Contract Services
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | March 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 50.58 Billion |
| Forecasted Market Value ( USD | $ 68.04 Billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
